Three trials with short-acting GLP-1RAs, exenatide and lixisenatide, showed slowed motor decline, though longer-acting formulations have not replicated this
Initial weight loss typically occurs within the first month, with ongoing, steady progress over the following months
These symptoms often diminish over time as the body adapts to the medication, though some individuals experience persistent symptoms throughout treatment
#Pharma #TopSellingDrugs #Biopharma #HealthcareInnovation #Oncology #Immunotherapy #ObesityCare #GLP1 #DrugDevelopment #PharmaceuticalIndustry #MarketInsights #PrecisionMedicine #HealthcareTrends 2025 Pharma Trends: Keytruda, Mounjaro, Ozempic Dominate Top-Selling Drugs : The pharmaceutical industry in 2025 is being dominated by breakthrough therapies across oncology, metabolic disorders, immunology, and cardiovascular care
As of now, Eliquis has been approved to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), for treatment of prophylaxis of DVT, and for treament of pulmonary embolism (PE)
In 2025, the company reported a strong +11.05% YoY revenue growth, driven by a favorable product mix: Eylea ($3.65B) remained a key ophthalmology contributor despite competitive pressure, Nubeqa ($2.8B) emerged as a major growth driver with expanding adoption in prostate cancer, and Xarelto ($2.75B) continued to generate significant revenue, although facing gradual decline due to patent expiries and generic competition
